| Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (8MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-440384
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.44038
Zusammenfassung
Focal early osteoarthritis (OA) or degenerative lesions account for 60% of treated cartilage defects each year. The current cell-based regenerative treatments have an increased failure rate for treating degenerative lesions compared to traumatic defects. Mesenchymal stem cells (MSCs) are an alternative cell source for treating early OA defects, due to their greater chondrogenic potential, ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags